Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 4/20 | 0.75 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.75 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.49 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.49 |
| ▸ | HRH1 | P35367 | 2/20 | 0.49 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.49 |
| ▸ | CX3CR1 | P49238 | 1/20 | 0.49 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.49 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.47 |
| ▸ | HRH2 | P25021 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1115911 | 1.00 | CHRM2 (0.75) | CHRM2CHRM1CHRM3CHRM5HRH1 | |
| Fumaric Acid SCHEMBL14696920 | 0.95 | CHRM2 (0.68) | CHRM2CHRM1CHRM3CHRM5HRH1 | |
| SCHEMBL10098313 | 0.90 | CHRM2 (0.71) | CHRM2CHRM1CHRM3CHRM5HRH1 | |
| SCHEMBL725535 | 0.88 | CHRM2 (0.77) | CHRM2CHRM1CHRM3CHRM5HRH1 | |
| SCHEMBL13175653 | 0.88 | CHRM2 (0.77) | CHRM2CHRM1CHRM3CHRM5HRH1 | |
| SCHEMBL14709412 | 0.88 | CHRM2 (0.77) | CHRM2CHRM1CHRM3CHRM5HRH1 | |
| SCHEMBL11297071 | 0.87 | CHRM2 (0.58) | CHRM2CHRM1CHRM3CHRM5HRH1 | |
| SCHEMBL11292330 | 0.87 | CHRM2 (0.58) | CHRM2CHRM1CHRM3CHRM5HRH1 | |
| SCHEMBL16819800 | 0.87 | CHRM2 (0.66) | CHRM2CHRM1CHRM3CHRM5HRH1 | |
| Fesoterodine SCHEMBL121127 | 0.86 | CHRM2 (1.00) | CHRM2CHRM1CHRM3CHRM5HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2855421-B1 | PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE 3,3-DIPHENYLPROPYLAMINES | CRYSTAL PHARMA SAU (ES) | 2018-03-21 | — | — | EP | disclosed |
| US-9440910-B2 | Reference markers for fesoterodine fumarate | ALEMBIC PHARMACEUTICALS LIMITED (IN) | 2016-09-13 | — | — | US | disclosed |
| US-20150175526-A2 | THE NOVEL REFERENCE MARKERS FOR FESOTERODINE FUMARATE | ALEMBIC PHARMACEUTICALS LIMITED (IN) | 2015-06-25 | — | — | US | disclosed |
| US-9012678-B2 | Processes for the preparation of fesoterodine | CADILA HEALTHCARE LIMITED (IN) | 2015-04-21 | — | — | US | disclosed |
| US-20140374284-A1 | NOVEL REFERENCE MARKERS FOR FESOTERODINE FUMARATE | ALEMBIC PHARMACEUTICALS LTD (IN) | 2014-12-25 | — | — | US | disclosed |
| EP-2780317-A2 | THE NOVEL REFERENCE MARKERS FOR FESOTERODINE FUMARATE | Alembic Pharmaceuticals Limited (IN) | 2014-09-24 | — | — | EP | disclosed |
| US-8722920-B2 | Process for obtaining 3, 3-diphenylpropylamines | CRYSTAL PHARMA S.A.U. (ES) | 2014-05-13 | — | — | US | disclosed |
| US-8722920-B2 | Process for obtaining 3, 3-diphenylpropylamines | CRYSTAL PHARMA S.A.U. (ES) | 2014-05-13 | — | — | US | disclosed |
| EP-2281801-B1 | Process for obtaining 3,3-diphenylpropylamines | CRYSTAL PHARMA SAU (ES) | 2014-01-08 | — | — | EP | disclosed |
| US-20130197260-A1 | PROCESSES FOR THE PREPARATION OF FESOTERODINE | CADILA HEALTHCARE LIMITED (IN) | 2013-08-01 | — | — | US | disclosed |
| WO-2013046194-A2 | THE NOVEL REFERENCE MARKERS FOR FESOTERODINE FUMARATE | ALEMBIC PHARMACEUTICALS LIMITED (IN) | 2013-04-04 | — | — | WO | disclosed |
| WO-2013046194-A2 | THE NOVEL REFERENCE MARKERS FOR FESOTERODINE FUMARATE | ALEMBIC PHARMACEUTICALS LIMITED (IN) | 2013-04-04 | — | — | WO | disclosed |
| WO-2013024415-A1 | AN IMPROVED METHOD FOR THE QUANTITATIVE DETERMINATION OF FESOTERODINE FUMARATE | ALEMBIC PHARMACEUTICALS LIMITED (IN) | 2013-02-21 | — | — | WO | disclosed |
| US-20120220797-A1 | PROCESS FOR OBTAINING 3, 3-DIPHENYLPROPYLAMINES | CURIA SPAIN, S.A.U. (ES) | 2012-08-30 | — | — | US | disclosed |
| US-20120220797-A1 | PROCESS FOR OBTAINING 3, 3-DIPHENYLPROPYLAMINES | CURIA SPAIN, S.A.U. (ES) | 2012-08-30 | — | — | US | disclosed |
| WO-2012025941-A2 | PROCESSES FOR THE PREPARATION OF FESOTERODINE | CADILA HEALTHCARE LIMITED (IN) | 2012-03-01 | — | — | WO | disclosed |
| EP-2281801-A1 | Process for obtaining 3,3-diphenylpropylamines | Ragactives, S.L.U. (ES) | 2011-02-09 | — | — | EP | disclosed |
| WO-2011012584-A1 | PROCESS FOR OBTAINING 3,3-DIPHENYLPROPYLAMINES | RAGACTIVES, S.L.U. (ES) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140374284-A1 | NOVEL REFERENCE MARKERS FOR FESOTERODINE FUMARATE | SHBG, KLK3, FES | CHRM2 230/4885CHRM1 928/4885CHRM3 268/4885 |
| US-20130197260-A1 | PROCESSES FOR THE PREPARATION OF FESOTERODINE | QDPR, FES, SULT1A1 | CHRM2 211/4885CHRM1 165/4885CHRM3 203/4885 |
| US-20150175526-A2 | THE NOVEL REFERENCE MARKERS FOR FESOTERODINE FUMARATE | SHBG, FES, KLK3 | CHRM2 163/4885CHRM1 739/4885CHRM3 146/4885 |
| US-20120220797-A1 | PROCESS FOR OBTAINING 3, 3-DIPHENYLPROPYLAMINES | ADRB3, CHRM3, CYP4F3 | CHRM2 8/4885CHRM1 12/4885CHRM3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.